BIM logo
BIM
bioMérieux

Continued Innovation And Market Leadership Will Ensure Future Success

AN
AnalystConsensusTarget
AnalystConsensusTarget
Not Invested
Consensus Narrative from 13 Analysts
Published
09 Feb 25
Updated
07 Aug 25
AnalystConsensusTarget's Fair Value
€123.54
0.9% overvalued intrinsic discount
07 Aug
€124.70
Loading
1Y
28.2%
7D
0.5%

Author's Valuation

€123.5

0.9% overvalued intrinsic discount

AnalystConsensusTarget Fair Value

Narrative
Updates8

Shared on01 May 25
Fair value Decreased 0.51%

Read more

Shared on23 Apr 25
Fair value Decreased 0.12%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Read more

Shared on17 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Read more

Shared on09 Apr 25
Fair value Decreased 0.17%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Read more

Shared on02 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Read more

Shared on26 Mar 25
Fair value Decreased 0.13%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Read more

Shared on19 Mar 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Read more

Shared on12 Mar 25
Fair value Increased 0.93%

AnalystConsensusTarget has decreased shares outstanding growth rate from -0.0% to -0.0%.

Read more